Click Therapeutics
Healthcare & Life Sci
Company overview
Click Therapeutics develops software-based medical treatments that physicians can prescribe to patients. Its lead product, CT-152 (Rejoyn), is FDA-cleared for depression as an add-on to antidepressants. CT-132 is in development for episodic migraine, and CT-155 is in development for the negative symptoms of schizophrenia. Click SE combines software with drugs, through partnerships with pharmaceutical companies including Otsuka Pharmaceutical and Boehringer Ingelheim.
David B. Klein founded Click Therapeutics in 2012 and coined the term Digital Therapeutics. The company is based in New York, where it was named to the DHNY Hall of Fame in 2025, a sign of how far the digital therapeutics field it helped define has come. Click Therapeutics is an H-1B sponsor.
- Industry
- Healthcare & Life Sci
- Headquarters
- 4 offices, United States